about
Trends in targeted prostate brachytherapy: from multiparametric MRI to nanomolecular radiosensitizersMagnetic resonance imaging-guided brachytherapy for cervical cancer: initiating a programMetal artefacts in MRI-guided brachytherapy of cervical cancerTechnical Note: Multipurpose CT, ultrasound, and MRI breast phantom for use in radiotherapy and minimally invasive interventions.Measurement of mean cardiac dose for various breast irradiation techniques and corresponding risk of major cardiovascular event.Doses to internal organs for various breast radiation techniques--implications on the risk of secondary cancers and cardiomyopathy.Customized vaginal vault brachytherapy with computed tomography imaging-derived applicator prototyping.Clinical evaluation of an endorectal immobilization system for use in prostate hypofractionated Stereotactic Ablative Body Radiotherapy (SABR).Three-dimensional-guided perineal-based interstitial brachytherapy in cervical cancer: A systematic review of technique, local control and toxicities.Predictive Parameters of Symptomatic Hematochezia Following 5-Fraction Gantry-Based SABR in Prostate Cancer.Dosimetric comparison of interstitial brachytherapy with multi-channel vaginal cylinder plans in patients with vaginal tumors.Experimental evaluation of an online gamma-camera imaging of permanent seed implantation (OGIPSI) prototype for partial breast irradiation.Quantitative CT assessment of a novel direction-modulated brachytherapy tandem applicator.Evaluation of a Machine-Learning Algorithm for Treatment Planning in Prostate Low-Dose-Rate Brachytherapy.Direction-modulated brachytherapy for high-dose-rate treatment of cervical cancer. I: theoretical design.Quantitative MRI assessment of a novel direction modulated brachytherapy tandem applicator for cervical cancer at 1.5T.Direction Modulated Brachytherapy for Treatment of Cervical Cancer. II: Comparative Planning Study With Intracavitary and Intracavitary-Interstitial Techniques.Efficacy of a rectal spacer with prostate SABR - first UK experience.Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: Early toxicity and quality-of life results from a randomized phase II clinical trial of one fraction of 19Gy or two fractions of 13.5Gy.Pattern of relapse and dose received by the recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer treated with single fraction 19 Gy high dose-rate brachytherapy.A comparative study of quality of life in patients with localized prostate cancer treated at a single institution: stereotactic ablative radiotherapy or external beam+high dose rate brachytherapy boost.Stereotactic ablative radiotherapy in the treatment of low and intermediate risk prostate cancer: Is there an optimal dose?Dosimetric impact of inter-observer catheter reconstruction variability in ultrasound-based high-dose-rate prostate brachytherapy.Electromagnetic tracking for catheter reconstruction in ultrasound-guided high-dose-rate brachytherapy of the prostate.Characterizing the impact of adaptive planning on image-guided perineal interstitial brachytherapy for gynecologic malignancies.Sensitivity of clinically relevant dosimetric parameters to contouring uncertainty in postimplant dosimetry of low-dose-rate prostate permanent seed brachytherapy.Diffuse infiltrative neurofibroma: a clinical, radiological, and histological conundrum.Clinical evaluation of an MRI-to-ultrasound deformable image registration algorithm for prostate brachytherapyPhase I/II Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation in Patients with High-Risk Prostate Cancer (SATURN): Early Toxicity and Quality of LifeVolumetric changes of the anterolateral thigh free flap following adjuvant radiotherapy in total parotidectomy reconstructionOnline gamma-camera imaging of 103Pd seeds (OGIPS) for permanent breast seed implantationPermanent breast seed implant dosimetry quality assuranceA comparison of postimplant dosimetry for (103)Pd versus (131)Cs seeds on a retrospective series of PBSI patientsThe clinical significance of persistent cancer cells on prostate biopsy after high-dose-rate brachytherapy boost for intermediate-risk prostate cancerHigh dose-rate brachytherapy boost for intermediate risk prostate cancer: Long-term outcomes of two different treatment schedules and early biochemical predictors of successOnce-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trialStereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation StudyAbsolute percentage of biopsied tissue positive for Gleason pattern 4 disease (APP4) appears predictive of disease control after high dose rate brachytherapy and external beam radiotherapy in intermediate risk prostate cancerTwo StereoTactic ablative radiotherapy treatments for localized prostate cancer (2STAR): Results from a prospective clinical trialMRI assisted focal boost integrated with HDR monotherapy study in low and intermediate risk prostate cancer (MARS): Results from a phase II clinical trial
P50
Q26738622-25557D5E-AE73-47D0-9E5E-7B8E18A77651Q26775790-9CFEA149-0F6B-49CB-8008-8F3AB3F1995BQ28078769-F4DA01B9-017E-4E36-AB45-3CFA466F57CDQ31090870-D10896B2-E61C-4A82-8971-64E407CDC115Q34384919-B06C8F3E-E5CD-4CC0-885F-D32BCAFC755DQ34521998-313F9F53-81ED-43D7-A26C-3F045F1590D8Q35550848-975A300C-467C-4CB3-8E2B-0AE8FEF9C5F1Q35686316-FBD0B9EC-EB78-4EBE-8417-7378588282E0Q38870581-69582A85-2AE4-41A4-9157-3D545A8086CDQ39879300-ACB8E922-1904-4B66-9ABA-D857589CFC88Q42256161-6E92502F-AB1D-4A86-9080-A684B8C9767FQ43779393-0DEBFEC8-9A59-4705-960A-330346B7DBA1Q45073935-C9013D59-3F45-4FE5-8A00-A37E52D61A15Q45948407-0224AAE9-5A67-4C10-A7A4-73703AFEADC6Q46036846-894B453B-9A2A-4321-8D4F-9E5EF6CDBFA4Q46185786-0AA48543-4F90-407F-8385-06FF3F085FBBQ46857365-03A75ECC-C140-44F3-A7BA-66E7039D98CBQ47226698-AAB2AAB5-4287-463D-AAD9-D1DFB129E0BDQ47624782-48DD8787-A15B-4E7F-880E-3E1436A23862Q47839632-EA9B546A-900F-4B7B-B980-2ECA22CC64A7Q48057515-86F39764-B3BA-4581-BABC-B62A1CA57831Q48661338-C2A2ACE6-E29B-4EE9-979A-9ED52AB7A182Q49844655-88220BE4-A0C6-4F85-8B79-B153B46FE6A9Q50615734-7483EB2B-8562-481A-B784-C43C995BE08EQ51773105-0C3F98ED-0038-4E22-8521-AEBAA01B3839Q52969271-6E6739C0-8534-4823-8027-519F78F4B3E7Q53058089-40280BE4-8276-4775-BC47-D98D2A027069Q57052956-7E139D94-6D9F-4020-A26E-A50BF1D81699Q57123897-113D4C0E-1E8A-4310-94E3-485DFF4DFBC5Q59417388-FC30D9CA-352D-4493-A5FE-563FE9E51FABQ81325478-412D2E00-BF65-401A-BB66-B56D3F88002BQ82146564-E4EC2002-9B16-47F3-A22C-B439EC8130FAQ82308713-A52EC163-CD6D-4B1D-BCAF-3FF7D7D4FAD5Q86168941-1E0B5799-432C-4FB5-BDD0-A0D910B17FDAQ86928775-B332D5B9-6032-4772-8701-0DE0031F35FDQ88090431-B7E02838-5231-479C-8CDB-DED7C6C11249Q90016339-A158AA92-8E17-462C-A214-D8EA9E077384Q90249792-2E6425D6-6ACB-47D0-9467-90D480AEBF4CQ90249867-0751BB82-72A6-43BA-AE7D-E0C99B2FE5E7Q90351990-FD5339BC-E350-42CD-8F62-4806F87A3C6E
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ananth Ravi
@ast
Ananth Ravi
@en
Ananth Ravi
@es
Ananth Ravi
@nl
Ananth Ravi
@sl
অনন্ত রবি
@bn
type
label
Ananth Ravi
@ast
Ananth Ravi
@en
Ananth Ravi
@es
Ananth Ravi
@nl
Ananth Ravi
@sl
অনন্ত রবি
@bn
prefLabel
Ananth Ravi
@ast
Ananth Ravi
@en
Ananth Ravi
@es
Ananth Ravi
@nl
Ananth Ravi
@sl
অনন্ত রবি
@bn
P106
P1153
36844612900
P21
P31
P496
0000-0003-4583-5741